MENU
+Compare
THNR
ETF ticker: NYSE ARCA
AS OF
Jul 2 closing price
Price
$22.98
Change
+$0.15 (+0.66%)

THNR stock forecast, quote, news & analysis

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index... Show more

Category: #Health
THNR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for THNR with price predictions
Jul 02, 2025

THNR's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for THNR moved out of overbought territory on June 16, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 instances where the indicator moved out of the overbought zone. In of the 5 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for THNR turned negative on June 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at .

THNR broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 11 cases where THNR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on THNR as a result. In of 13 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where THNR advanced for three days, in of 60 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 32 cases where THNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Market Cap

The average market capitalization across the Amplify Weight Loss Drug & Treatment ETF ETF is 144.65B. The market cap for tickers in the group ranges from 343.08M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is ALT at 343.08M.

High and low price notable news

The average weekly price growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was 2%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 1%. HIMS experienced the highest price growth at 15%, while ALT experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was -14%. For the same stocks of the ETF, the average monthly volume growth was -2% and the average quarterly volume growth was 75%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 83
Price Growth Rating: 60
SMR Rating: 58
Profit Risk Rating: 71
Seasonality Score: 9 (-100 ... +100)
View a ticker or compare two or three
THNR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details